- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05913544
Kort integrativ og nevrokognitiv terapi for unge voksne med borderline personlighetsforstyrrelse (SINTYA)
Kort integrativ og nevrokognitiv terapi for unge voksne med borderline personlighetsforstyrrelse: en studiemodell for impulsivitetshåndtering
Borderline personality disorder (BPD) is a severe, high-suicidal psychiatric disorder associated with impulsive, endangering behaviors. Young patients between 16 and 25 years old do not respond to traditional psychotherapies, which are often long and not adapted to their neurocognitive alterations linked to early trauma. The study authors hypothesize the SINTYA therapy program (one group session and one individual session weekly for 10 weeks) would reduce the level of impulsivity and clinical symptomatology (severity of the BPD; emotional regulation difficulties; dissociative symptoms; aggressiveness; ruminations; the number of self-destructive behaviors and suicidal acts; impulsive behaviors; level of suicide risk and hopelessness; the number of psychiatric hospitalizations and emergency visits for psychiatric reasons; and finally improving psychosocial functioning).
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Nîmes, Frankrike
- CHU de Nîmes
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Diagnosis of BPD according to DSM-5 criteria and BPQ-80 scale.
- High BPD severity level: ZAN-BPD (score ≥ 18/36).
- Understand, write and read French.
- Be able to understand the nature, purpose and methodology of the study and agree to cooperate during evaluations.
- Have signed the informed consent.
- For minor patients, have signed the parental consent by at least one holder of parental authority.
Exclusion Criteria:
- Refusal to participate.
- Existence of a neurological pathology or cerebral sequelae of organic origin which could affect neurocognitive performance.
- Intelligence quotient < 70.
- Lifetime diagnosis of schizoaffective disorder or schizophrenia (MINI-7).
- Previous or current participation in specific psychotherapy for BPD.
- Subject deprived of liberty (by judicial or administrative decision) and/or protected by law.
- Inclusion in another study including psychotherapy for the duration of the study.
- Inclusion in a drug RIPH1 study or in a REC study (European regulation of clinical trials) for the entire duration of the study.
- Subject in period of exclusion from another research protocol.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Ingen inngripen: Styre
|
|
|
Eksperimentell: SINTYA-gruppen
|
10-week psychotherapy program consisting of a weekly 1h30 hour group therapy session plus 1 hour individual therapy session |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Variation in explicit impulsivity between groups
Tidsramme: Baseline
|
UPPS-S (Impulsive Behavior Scale Short version score) |
Baseline
|
|
Variation in explicit impulsivity between groups
Tidsramme: Month 4
|
UPPS-S (Impulsive Behavior Scale Short version score) |
Month 4
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Variation in explicit impulsivity between groups
Tidsramme: Month 7
|
UPPS-S (Impulsive Behavior Scale Short version score) |
Month 7
|
|
Variation in impulsiveness between groups
Tidsramme: Baseline
|
Barratt Impulsiveness Scale (BIS-11) (score out of 120) |
Baseline
|
|
Variation in impulsiveness between groups
Tidsramme: Month 4
|
Barratt Impulsiveness Scale (BIS-11) (score out of 120) |
Month 4
|
|
Variation in impulsiveness between groups
Tidsramme: Month 7
|
Barratt Impulsiveness Scale (BIS-11) (score out of 120) |
Month 7
|
|
BPD severity level between groups
Tidsramme: Baseline
|
Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) (score out of 36) |
Baseline
|
|
BPD severity level between groups
Tidsramme: Month 4
|
Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) (score out of 36) |
Month 4
|
|
BPD severity level between groups
Tidsramme: Month 7
|
Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) (score out of 36) |
Month 7
|
|
Emotional regulation capacities between groups
Tidsramme: Baseline
|
Difficulties in Emotion Regulation Scale (DERS-18) |
Baseline
|
|
Emotional regulation capacities between groups
Tidsramme: Month 4
|
Difficulties in Emotion Regulation Scale (DERS-18) |
Month 4
|
|
Emotional regulation capacities between groups
Tidsramme: Month 7
|
Difficulties in Emotion Regulation Scale (DERS-18) |
Month 7
|
|
Dissociative symptoms between groups
Tidsramme: Baseline
|
Dissociative Experiences Scale (DES): a score of 25 or higher is predictive of dissociative disorder |
Baseline
|
|
Dissociative symptoms between groups
Tidsramme: Month 4
|
Dissociative Experiences Scale (DES): a score of 25 or higher is predictive of dissociative disorder |
Month 4
|
|
Dissociative symptoms between groups
Tidsramme: Month 7
|
Dissociative Experiences Scale (DES): a score of 25 or higher is predictive of dissociative disorder |
Month 7
|
|
Aggression between groups
Tidsramme: Baseline
|
Aggression Questionnaire (AQ-12) |
Baseline
|
|
Aggression between groups
Tidsramme: Month 4
|
Aggression Questionnaire (AQ-12) |
Month 4
|
|
Aggression between groups
Tidsramme: Month 7
|
Aggression Questionnaire (AQ-12) |
Month 7
|
|
Ruminations between groups
Tidsramme: Baseline
|
Rumination Reflection Questionnaire (RRQ) |
Baseline
|
|
Ruminations between groups
Tidsramme: Month 4
|
Rumination Reflection Questionnaire (RRQ) |
Month 4
|
|
Ruminations between groups
Tidsramme: Month 7
|
Rumination Reflection Questionnaire (RRQ) |
Month 7
|
|
Number of self-destructive behaviors between groups
Tidsramme: Baseline
|
Number of self-destructive/self-mutilatory/parasuicidal acts reported by the patient in a clinical interview |
Baseline
|
|
Number of self-destructive behaviors between groups
Tidsramme: Month 4
|
Number of self-destructive/self-mutilatory/parasuicidal acts reported by the patient in a clinical interview |
Month 4
|
|
Number of self-destructive behaviors between groups
Tidsramme: Month 7
|
Number of self-destructive/self-mutilatory/parasuicidal acts reported by the patient in a clinical interview |
Month 7
|
|
Number of impulsive behaviors between groups
Tidsramme: Baseline
|
Number of impulsive behaviors (food, motor vehicles, sexual, drug-related) |
Baseline
|
|
Number of impulsive behaviors between groups
Tidsramme: Month 4
|
Number of impulsive behaviors (food, motor vehicles, sexual, drug-related) |
Month 4
|
|
Number of impulsive behaviors between groups
Tidsramme: Month 7
|
Number of impulsive behaviors (food, motor vehicles, sexual, drug-related) |
Month 7
|
|
Level of suicide risk between groups
Tidsramme: Baseline
|
Columbia-Suicide Severity Rating Scale (C-SSRS) |
Baseline
|
|
Level of suicide risk between groups
Tidsramme: Month 4
|
Columbia-Suicide Severity Rating Scale (C-SSRS) |
Month 4
|
|
Level of suicide risk between groups
Tidsramme: Month 7
|
Columbia-Suicide Severity Rating Scale (C-SSRS) |
Month 7
|
|
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Tidsramme: 12 Months prior to inclusion
|
Information taken from patient medical file |
12 Months prior to inclusion
|
|
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Tidsramme: Baseline
|
Information taken from patient medical file |
Baseline
|
|
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Tidsramme: Month 4
|
Information taken from patient medical file |
Month 4
|
|
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Tidsramme: Month 7
|
Information taken from patient medical file |
Month 7
|
|
Psychosocial functioning between groups
Tidsramme: Baseline
|
Functional Assessment Staging Tool (FAST) |
Baseline
|
|
Psychosocial functioning between groups
Tidsramme: Month 4
|
Functional Assessment Staging Tool (FAST) |
Month 4
|
|
Psychosocial functioning between groups
Tidsramme: Month 7
|
Functional Assessment Staging Tool (FAST) |
Month 7
|
|
Implicit impulsivity between groups
Tidsramme: Baseline
|
Continuous Performance Test (CPT) |
Baseline
|
|
Implicit impulsivity between groups
Tidsramme: Month 4
|
Continuous Performance Test (CPT) |
Month 4
|
|
Implicit impulsivity between groups
Tidsramme: Month 7
|
Continuous Performance Test (CPT) |
Month 7
|
|
Neurocognitive evaluation of implicit impulsivity between groups
Tidsramme: Baseline
|
Emotional Stroop (SE) customized to the study |
Baseline
|
|
Neurocognitive evaluation of implicit impulsivity between groups
Tidsramme: Month 4
|
Emotional Stroop (SE) customized to the study |
Month 4
|
|
Neurocognitive evaluation of implicit impulsivity between groups
Tidsramme: Month 7
|
Emotional Stroop (SE) customized to the study |
Month 7
|
|
Risk taking between groups
Tidsramme: Baseline
|
Balloon Analogue Risk Task (BART) |
Baseline
|
|
Risk taking between groups
Tidsramme: Month 4
|
Balloon Analogue Risk Task (BART) |
Month 4
|
|
Risk taking between groups
Tidsramme: Month 7
|
Balloon Analogue Risk Task (BART) |
Month 7
|
|
Decision making under risk conditions between groups
Tidsramme: Baseline
|
Game Dice Task (GDT) |
Baseline
|
|
Decision making under risk conditions between groups
Tidsramme: Month 4
|
Game Dice Task (GDT) |
Month 4
|
|
Decision making under risk conditions between groups
Tidsramme: Month 7
|
Game Dice Task (GDT) |
Month 7
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Clémentine Estric, CHU de Nimes
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- NIMAO/2022-1/CE-01
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
All IPD that underlie results in a publication
IPD-delingstidsramme
Upon publication
Tilgangskriterier for IPD-deling
The IPD will be made available to other researchers upon reasonable request to the corresponding author
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
- ANALYTIC_CODE
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .